Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
1999-01-22
2003-12-30
Harris, Alana M. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S007100, C435S007230, C435S325000, C435S352000, C435S354000, C435S029000, C435S194000, C435S357000, C435S366000, C435S367000, C435S375000, C514S012200, C514S492000, C424S277100, C530S350000, C436S063000, C436S064000, C436S086000
Reexamination Certificate
active
06670139
ABSTRACT:
BACKGROUND OF THE INVENTION
Apoptosis is a form of cell death that is carried out by a specialized intrinsic machinery. Although the knowledge about the biochemical mechanisms of apoptosis is fragmentary, it appears that signalling pathways that regulate apoptosis converge on a conserved machinery that disassembles a cell. An essential part of this machinery is a family of proteases related to interleukin-1B-converting enzyme (ICE) (Lazebnik, Y. A., et al.,
Proc. Natl. Acad. Sci. USA
, 92:9042-9046 (1995); (Lazebnik, Y. A., et al.,
Nature
, 371:346-347 (1994); Nicholson, D. W., et al.,
Nature
, 376:37-43 (1995); Yuan, J., et al.,
Cell
, 641-652:641-652 (1993)). ICE-like proteases (ILPs) are expressed as inactive pro-enzymes that have to be activated to cleave their substrates and to contribute to apoptosis (Horvitz, H. R., et al.,
Cold Spring Harb. Symp. Quant. Biol
., 59:377-385 (1994); Oltvai, Z. N. and Korsmeyer, S. J.,
Cell
, 79:189-192 (1994)).
Cancer chemotherapy kills cells by induction of apoptosis (Lowe, S. W., et al.,
Cell
, 74:957-967 (1993); Fisher, D. E.,
Cell
, 78:539-542 (1994)). Defects of apoptosis common in cancer cells contribute to tumor regression and appear to be responsible for the failure of current cancer chemotherapy. Alternatively excess apoptosis can lead to neurodegenerative diseases (e.g., Huntington's Disease, Alzheimers Disease).
Therefore, more effective chemotherapeutic agents are needed.
SUMMARY OF THE INVENTION
The present invention relates to a method of identifying a compound (agent) which modulates apoptosis in transformed cells. In one embodiment, the invention is a method of identifying a compound which selectively activates apoptosis in transformed cells. In an alternative embodiment, the present invention can be used as a method of identifying a compound which inhibits apoptosis in cells.
The present method is carried out in a cell-free system in which the combination or reagents is determined by whether the assay is used to identify a compound which selectively activates apoptosis in transformed cells or a compound which inhibits apoptosis in cells.
In the embodiment in which a compound which selectively activates apoptosis in transformed cells is to be identified, the following reagents are combined to produce a test sample: the compound to be assessed; apoptotic machinery and a signal which activates the apoptotic machinery (e.g., obtained from cellular extracts of transformed cells); and an inhibitor of apoptosis. The combination is maintained under conditions appropriate for activation of apoptosis; activation of apoptosis is detected in the presence of the compound to be assessed by detecting or assessing an event indicative of recoupling of the apoptotic machinery. Recoupling of the apoptotic machinery indicates that the compound to be assessed selectively activates apoptosis in transformed cells.
In the embodiment in which an inhibitor of apoptosis is to be identified, the following reagents are combined: a compound to be assessed and apoptotic machinery and a signal which activates, or is capable of activating, the apoptotic machinery. The combination is maintained under conditions appropriate for activation of apoptosis; inhibition of apoptosis is detected in the presence of the compound to be assessed by detecting uncoupling of the apoptotic machinery. Uncoupling of the apoptotic machinery indicates that the compound to be assessed inhibits apoptosis in cells.
The invention also relates to a method of selectively killing transformed cells, wherein the transformed cell is contacted with a compound which selectively activates apoptosis in transformed cells, as described herein. The invention also relates to methods of treating diseases associated with defective apoptotic machinery (e.g., cancer, neurodegenerative disease). In one embodiment, the invention relates to a method of treating cancer in an individual, wherein an effective amount of a compound which selectively activates apoptosis in transformed cells is administered to the individual. In another embodiment, the invention relates to a method of treating a neurodegenerative disease in an individual, wherein an effective amount of a compound which modulates apoptosis, as identified herein, is administered to an individual.
The methods of the present invention are useful for defining the biochemical mechanisms of apoptosis. In addition, the invention provides an assay to identify compounds which modulate (inhibit, activate) apoptosis, supplying new drugs which target defective apoptotic machinery associated with disease (e.g., cancer, neurodegenerative diseases such as Huntington's Disease and Alzheimers Disease).
The invention further provides an alternative to current chemotherapy techniques. Current chemotherapy results in increasing the apoptotic signal by inflicting cellular damage in cancer cells and normal cells. However, this approach fails when the signal required to exceed the threshold in drug-resistant cells is sufficient to overcome the threshold in untransformed cells. As described herein, transformed cells harbor a signal which is capable of activating the apoptotic machinery in transformed cells. This signal, which is absent in untransformed cells, is uncoupled from the apoptotic machinery in drug-resistant cells. Thus, in contrast to current chemotherapy, compounds identified as described herein, which recouple the signal to the apoptotic machinery, will selectively kill these cells, and result in a more effective treatment for cancer.
REFERENCES:
patent: WO 95/05738 (1995-03-01), None
patent: WO 96/20721 (1996-07-01), None
patent: WO 96/26280 (1996-08-01), None
American Type Culture Collection. Catalogue of Cell Lines and Hybridomas, 7th Edition. p. 170, 1992.*
Goldstein, W., “Apoptosis, When Suicide is Good”Harbor Transcript, A Newsletter of Cold Spring Harbor Laboratory, 14(1):1, 4-6, (1996).
Liu, Xuesong, et al., “Induction of Apoptotic Program in Cell-Free Extracts: Requirements for dATP and Cytochrome c”,Cell, 86:147-157, (1996).
Lazebnik, Y.A., et al., “Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution”,Proc. Natl. Acad. Sci. USA, 92:9042-9046, (1995).
Nicholson, D.W., et al., “Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis”,Nature, 376:37-43, (1995).
Lazebnik, Y.A., et al., “Nuclear Events of Apoptosis In Vitro in Cell-free Mitotic Extracts: A Model System for Analysis of the Active Phase of Apoptosis”,Jour. of Cell Biol., 123(1):7-22, (1993).
Newmeyer, D.D., et al., “Cell-Free Apoptosis in Xenopus Egg Extracts: Inhibition by Bcl-2 and Requirement for an Organelle Fraction Enriched in Mitochondria”,Cell, 79:353-364, (1994).
Cosulich, S.C., et al., “Bcl-2 regulates activation of apoptotic proteases in a cell-free system”,Current Biology, 6(8):997-1005, (1996).
Lazebnik, Y.A., et al., “Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE”,Nature, 371:346-347, (1994).
Enari, M., et al., “Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis”,Nature, 380:723-726, (1996).
Martin, S.J., et al., “Cell-free reconstitution of Fas-, UV radiation- and ceramide-induced apoptosis”,The EMBO Jour., 14(21):5191-5200, (1995).
Fisher, D.E., “Apoptosis in Cancer Therapy: Crossing the Threshold”,Cell, 78:539-542 (1994).
Lowe, S.W., et al., “p53-Dependent Apoptosis Modulates the Cytotoxicity of Anticancer Agents”,Cell, 74:957-967, (1993).
Rao, L. et al., “The adenovirus E1A proteins induce apoptosis, which in inhibited by the E1B 19kDa and Bcl-2 proteins”,Proc. Natl. Acad. Sci. USA, 89:7742-7746, (1992).
Lowe, S.W., and Ruley, H.E., “Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis”,Genes&Development, 7:535-545, (1993).
Lowe, S.W., et al., “Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells”,Proc. Natl. Acad. Sci. USA, 91:2026-2030 (1994).
Lazebnik, Y.A., et al., “Characterization of the execution pha
Fearnhead Howard O.
Lazebnik Yuri
Lowe Scott William
McCurrach Mila Elena
Cold Spring Harbor Laboratory
Hamilton Brook Smith & Reynolds P.C.
Harris Alana M.
LandOfFree
Cell-free assay using oncogene-induced apoptosis to identify... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cell-free assay using oncogene-induced apoptosis to identify..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell-free assay using oncogene-induced apoptosis to identify... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3115068